{
    "clinical_study": {
        "@rank": "33650", 
        "acronym": "TRI-LARC", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Arm", 
                "arm_group_type": "Experimental", 
                "description": "50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT"
            }, 
            {
                "arm_group_label": "Control Arm", 
                "arm_group_type": "No Intervention", 
                "description": "50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique"
            }
        ], 
        "brief_summary": {
            "textblock": "The study aims to compare the incidence of acute grade 2 GI toxicity in the Control 3-D\n      Conformal Radiotherapy compared to the Intensity Modulated Radiotherapy (IMRT) arm for\n      locally advanced rectal cancer."
        }, 
        "brief_title": "Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer", 
        "completion_date": {
            "#text": "July 2030", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced Rectal Cancer", 
        "condition_browse": {
            "mesh_term": "Rectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Pre-operative radiotherapy (RT) or chemo-radiotherapy (CRT) is internationally accepted as\n      standard practice in the management of locally advanced rectal cancer.\n\n      Multiple randomised trials have proved pre-operative CRT and RT, compared to surgery alone,\n      reduce local recurrence, even prior to optimal surgery, and may improve survival for T3\n      circumferential resection margin (CRM) negative patients.\n\n      This study aims to determine if  3-DCRT or IMRT result in lower incidence of grade 2 GI\n      toxicities.\n\n      Acute toxicities will be assessed weekly during radiotherapy, and at 2 and 4 week post\n      treatment.\n\n      Late toxicities will be assessed at 3, 6, 9, 12, 18, 24 months post treatment, and annually\n      to 10 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients undergoing pre-operative pelvic chemo-radiotherapy for histologically\n             confirmed rectal adenocarcinoma, with the following staging: cT3N0-2, cT4N0-2,\n             cT(any)N1-2, cT(any)N(any) CRM at-risk [AJCC version V]\n\n          -  Staging / imaging of pelvis with MRI, and CT Thorax/Abdomen\n\n          -  No evidence of metastatic disease\n\n          -  ECOG Performance Status 0 - 2\n\n          -  Age  > or equal to 18 years\n\n          -  Provision of written informed consent in line with ICH-GCP guidelines\n\n        Exclusion Criteria:\n\n          -  Previous radiotherapy to the pelvic region\n\n          -  Patients in whom induction chemotherapy has been delivered prior to chemo-\n             radiotherapy\n\n          -  History of inflammatory bowel disease\n\n          -  Previous hip replacement\n\n          -  Previous bowel surgery (excluding procedures/operations which would not result in\n             small bowel adhesions - at the discretion of the Principal Investigator)\n\n          -  Patients with other syndromes/conditions associated with increased radiosensitivity\n\n          -  Any other co-existing malignancies within the past 5 years other than non- melanoma\n             skin cancer\n\n          -  Pregnancy or lactation at the time of proposed randomisation\n\n          -  Evidence of any other significant clinical disorder or laboratory finding that makes\n             it undesirable for the patient to participate in the study or if it is felt by the\n             research / medical team that the patient may not be able to comply with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "268", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151019", 
            "org_study_id": "ICORG 12-38"
        }, 
        "intervention": {
            "arm_group_label": "Experimental Arm", 
            "description": "IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT", 
            "intervention_name": "IMRT", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "last_name": "Contact Person", 
                "phone": "01-8093000"
            }, 
            "facility": {
                "address": {
                    "city": "Dublin", 
                    "country": "Ireland", 
                    "zip": "9"
                }, 
                "name": "St Luke's Centre for Radiation Oncology at Beaumont Hospital"
            }, 
            "investigator": {
                "last_name": "Brian O'Neill, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Phase II Study of Pre-operative 3-D Conformal Radiotherapy (3-DCRT) Versus Intensity Modulated Radiotherapy (IMRT) for Locally Advanced Rectal Cancer", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Ireland: Irish Medicines Board (IMB)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine if there is a reduction in the incidence of grade 2 or higher acute GI toxicity in the IMRT arm, as compared to the Control / 3-D arm, graded by the NCI-NTCAE Version 4", 
            "measure": "Reduction in incidence of grade 2 or higher GI toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the incidence of acute grade > 2 GU toxicity in the IMRT arm, as comparted to the Control / 3-D arm, graded by teh NCI-CTCAE Version 4", 
                "measure": "Compare incidence of acute grade > 2 GU toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "description": "To evaluate the incidence of late GI and GU toxicity graded by the NCI-CTCAE Version 4", 
                "measure": "Evaluate incidence of late GI and GU toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "description": "To estimate the rate of loco-regional control by assessing CT / MRI imaging / biopsy", 
                "measure": "Rate of loco-regional control", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "description": "To assess QoL according to the EORTC QLQ-C30 and EORTC QLQ-CR29", 
                "measure": "Assess quality of life", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "description": "To estimate the rate of disease-free survival", 
                "measure": "Rate of disease free survival", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "description": "To estimate the overall survival rate", 
                "measure": "Estimate overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }
        ], 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}